Which drugs are defined as antiarrhythmics in ACLS protocols?

In the context of Advanced Cardiovascular Life Support (ACLS) protocols, the classification of drugs is essential for effective management of cardiac arrhythmias. The choice that includes amiodarone and lidocaine is correct because both of these medications are specifically utilized as antiarrhythmics within ACLS guidelines.

Amiodarone is recognized for its broad-spectrum activity against a variety of arrhythmias, particularly in the control of ventricular tachycardia and ventricular fibrillation. It works by prolonging the action potential and refractory period in myocardial tissue, helping to stabilize heart rhythms.

Lidocaine, on the other hand, is primarily used for the treatment of ventricular arrhythmias derived from myocardial ischemia. It functions as a sodium channel blocker, decreasing automaticity and stabilizing the myocardium to prevent further arrhythmic events.

Both drugs are integral to the treatment protocols outlined in ACLS, directly addressing life-threatening heart rhythm disorders, thus classifying them as antiarrhythmics.